Integra LifeSciences (NASDAQ:IART) Sets New 1-Year High – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares hit a new 52-week high on Friday . The company traded as high as $17.83 and last traded at $17.3850, with a volume of 133133 shares changing hands. The stock had previously closed at $17.56.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on IART shares. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Finally, Truist Financial lowered their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Price Performance

The company has a 50 day moving average price of $12.32 and a 200 day moving average price of $11.95. The firm has a market cap of $1.33 billion, a PE ratio of -2.64, a price-to-earnings-growth ratio of 1.12 and a beta of 1.24. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $25,000. Osaic Holdings Inc. grew its holdings in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the last quarter. GAMMA Investing LLC increased its position in Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after buying an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter worth $124,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.